All
Laser eye safety: How to keep you, your staff and your patients seeing clearly
July 1st 2008With the continued introduction of laser devices with unique delivery systems and wavelengths, the issue of eye safety is becoming increasingly complicated. Consistent and competent eye safety procedures for operator, patient, observer and assistant are crucial to a safe and successful laser practice. Despite our increased knowledge of lasers and laser safety, eye injuries in the workplace are still a common problem, with many injuries going undetected well after the incident.
Treating Asian skin: Fast-growing population requires delicate treatment
July 1st 2008Although Asians are the fastest-growing population group in the United States, most dermatologists are not familiar with differences in the skin of Asians as compared to Caucasian patients. Signs of aging are different, and more delicate treatment is needed for sensitive Asian skin.
Vascular anomalies: Clinicians must treat underlying disease in children with port wine stains
July 1st 2008When children present with port wine stains, clinicians should consider serious conditions and underlying disease. Vascular anomalies can be classified into two major groups: vascular tumors, which infantile hemangiomas are the most frequent, and vascular malformations.
Rosacea treatments: Delayed-release doxycycline 40 mg and doxycycline 100 mg face off
July 1st 2008Study shows comparable efficacy and onset of therapeutic effect with doxycycline 40 mg (delayed release) once daily or doxycycline 100 mg once daily for treatment of rosacea, with some differences in adverse effects.
Tinea capitis: Fungal isolates highly susceptible to terbinafine
July 1st 2008Fungal isolates from patients with tinea capitis participating in international clinical trials were tested for in vitro susceptibility to terbinafine. The results showed terbinafine had potent activity against all 301 dermatophytes tested. There was no difference in MIC values comparing U.S. and non-U.S. isolates of the same organism.
PHOENIX study evaluates the safety, efficacy of ustekinumab in treating plaque psoriasis
July 1st 2008PHOENIX 1 is a phase 3 study evaluating the efficacy and safety of ustekinumab (Centocor), a fully human interleukin-12/23p40 monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis. The study randomized 766 patients to receive ustekinumab 45 mg, ustekinumab 90 mg or placebo at weeks zero and four. Data from 52 weeks and 76 weeks show high proportions of patients are maintaining PASI 75 responses with maintenance injections every 12 weeks.
Promising outlook: Study shows efalizumab provides long-term hope for disease-free intervals
July 1st 2008The results of a three-year study with efalizumab show that patients with moderate-to-severe psoriasis are able to maintain high PASI scores, reflecting long-term hope for disease-free intervals.
Express treatment: Infliximab maintenance treatment controls psoriasis
July 1st 2008The phase 3 EXPRESS II trial data show infliximab (Remicade, Centocor) maintenance treatment with regularly administered infusions is associated with better psoriasis control and fewer infusion reactions than intermittent, as-needed dosing. A composite analysis of infliximab phase 2 and 3 study data shows consistently dramatic improvements across all four body regions evaluated in the studies.
Broad-spectrum knowledge: Understanding sunscreen efficacy testing, rating
July 1st 2008The proposed new rules for sunscreens issued by the FDA have focused attention on understanding the different methods available for assessing UVA protection. Considering the limitations of various tests and real-world product use patterns, it is important that a sunscreen demonstrate both high levels of in vivo and in vitro protection against UVA as well as a high SPF level.
Preventing photogenotoxicity: Stable, broad-spectrum protection critical for sunscreen
July 1st 2008In vitro studies evaluated the transmission profiles and photostability of three commercially available sunscreens, as well as their activity for protecting against UV-induced cytotoxicity and genotoxicity.
After the burn: Encouraging results from autologous fibroblast therapy in treatment of injuries
July 1st 2008Autologous fibroblast therapy (Isolagen, Isolagen, Inc.) has been used to achieve functional and cosmetic improvements in patients with acute and chronic burn injuries involving the face, neck, hands, and chest. The treatment was safe and well-tolerated and associated with high patient satisfaction.
Military gains: Regenerative medicine project will impact burn, wound therapies for civilians, too
July 1st 2008The Department of Defense (DOD) has awarded a multimillion-dollar research grant to develop new therapies for wounded soldiers, which may hasten the pace at which unique, innovative burn and wound healing and cosmetic procedures become commonly used in treating civilians.
Legal: Using patient videos for teaching requires informed consent
July 1st 2008Dr. Photo has lectured at numerous American Academy of Dermatology meetings. His lectures are well-attended and receive the highest attendee rankings. His PowerPoint presentations are always noted for their exceptional clarity.
Opinions: Growing medspa industry, shrinking economy impact practices
July 1st 2008Over the past 10 to 15 years, there has been a boom in the phenomenon commonly known as "medspas" - an outgrowth of the purely Aesthetic day spa, combining herbal wraps and massages with medical or near-medical therapies, such as microdermabrasion and chemical peels, and progressing into lasers, fillers and Botox treatments.
DermTech names Australian skin cancer authority to its Melanoma Advisory Board
July 1st 2008La Jolla, Calif. - DermTech, a biotech company that develops molecular diagnostics for the early detection of melanoma and other diseases, has named skin cancer expert Scott Menzies, M.B., B.S., Ph.D., to its Melanoma Advisory Board, PRNewswire reports.